Treatment of Low HDL-C Subjects with the CETP Modulator Dalcetrapib Increases Plasma Campesterol Only in Those Without ABCA1 And/or ApoA1 Mutations

Overview

Journal Lipids

Specialty Biochemistry

Date 2014 Oct 5

PMID 25281277

Citations 4

Authors

Eric J Niesor

David Kallend

Darren Bentley

John J P Kastelein

G Kees Hovingh

Erik S G Stroes

Affiliations

Soon will be listed here.

Abstract

We investigated the effect of dalcetrapib treatment on phytosterol levels in patients with familial combined hyperlipidemia (FCH) or familial hypoalphalipoproteinemia (FHA) due to mutations in apolipoprotein A1 (ApoA1) or ATP-binding cassette transporter A1 (ABCA1). Patients (n = 40) with FCH or FHA received dalcetrapib 600 mg or placebo in this 4-week, double-blind, crossover study. Lipids, apolipoproteins, cholesteryl ester transfer protein (CETP) activity and mass, and phytosterols were assessed. Dalcetrapib increased high-density lipoprotein cholesterol (HDL-C) and ApoA1 levels to a similar extent in FHA (+22.8, +13.9%) and FCH (+18.4, +12.1%), both p < 0.001 vs. placebo. Changes in CETP activity and mass were comparable for FHA (-31.5, +120.9%) and FCH (-26.6, +111.9%), both p < 0.0001 vs. placebo. Campesterol and lathosterol were unchanged in FHA (+3.8, +3.0%), but only campesterol was markedly increased in FCH (+25.0%, p < 0.0001 vs. placebo). Campesterol increased with dalcetrapib treatment in FCH but not in FHA, despite comparable HDL-C and ApoA1 increases, suggesting that ApoA1 and/or ABCA1 is essential for HDL lipidation by enterocytes in humans.

Citing Articles

The Plasma Distribution of Non-cholesterol Sterol Precursors and Products of Cholesterol Synthesis and Phytosterols Depend on HDL Concentration.

Nunes V, da Silva E, Ferreira G, Assis S, Cazita P, Nakandakare E Front Nutr. 2022; 9:723555.

PMID: 35299760 PMC: 8921769. DOI: 10.3389/fnut.2022.723555.

Microarray analysis of long non-coding RNA expression profiles in low high-density lipoprotein cholesterol disease.

Wang X, Guo S, Hu Y, Guo H, Zhang X, Yan Y Lipids Health Dis. 2020; 19(1):175.

PMID: 32723322 PMC: 7388226. DOI: 10.1186/s12944-020-01348-x.

Associations of the APOC3 rs5128 polymorphism with plasma APOC3 and lipid levels: a meta-analysis.

Song Y, Zhu L, Richa M, Li P, Yang Y, Li S Lipids Health Dis. 2015; 14:32.

PMID: 25928461 PMC: 4457007. DOI: 10.1186/s12944-015-0027-0.

Will Lipidation of ApoA1 through Interaction with ABCA1 at the Intestinal Level Affect the Protective Functions of HDL?.

Niesor E Biology (Basel). 2015; 4(1):17-38.

PMID: 25569858 PMC: 4381214. DOI: 10.3390/biology4010017.

References

Gylling H, Hallikainen M, Kolehmainen M, Toppinen L, Pihlajamaki J, Mykkanen H . Cholesterol synthesis prevails over absorption in metabolic syndrome. Transl Res. 2007; 149(6):310-6. DOI: 10.1016/j.trsl.2006.11.012. View

Kruit J, Groen A, van Berkel T, Kuipers F . Emerging roles of the intestine in control of cholesterol metabolism. World J Gastroenterol. 2006; 12(40):6429-39. PMC: 4100631. DOI: 10.3748/wjg.v12.i40.6429. View

Maugeais C, Perez A, von der Mark E, Magg C, Pflieger P, Niesor E . Evidence for a role of CETP in HDL remodeling and cholesterol efflux: role of cysteine 13 of CETP. Biochim Biophys Acta. 2013; 1831(11):1644-50. DOI: 10.1016/j.bbalip.2013.07.007. View

Brunham L, Kruit J, Pape T, Parks J, Kuipers F, Hayden M . Tissue-specific induction of intestinal ABCA1 expression with a liver X receptor agonist raises plasma HDL cholesterol levels. Circ Res. 2006; 99(7):672-4. DOI: 10.1161/01.RES.0000244014.19589.8e. View

Leichtle A, Helmschrodt C, Ceglarek U, Shai I, Henkin Y, Schwarzfuchs D . Effects of a 2-y dietary weight-loss intervention on cholesterol metabolism in moderately obese men. Am J Clin Nutr. 2011; 94(5):1189-95. DOI: 10.3945/ajcn.111.018119. View

Niesor E, Magg C, Ogawa N, Okamoto H, von der Mark E, Matile H . Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport. J Lipid Res. 2010; 51(12):3443-54. PMC: 2975716. DOI: 10.1194/jlr.M008706. View

SUTHERLAND W, Robertson M, Williamson S, NYE E . Plasma noncholesterol sterols in male distance runners and sedentary men. Eur J Appl Physiol Occup Physiol. 1991; 63(2):119-23. DOI: 10.1007/BF00235180. View

Nunes V, Leanca C, Panzoldo N, Parra E, Cazita P, Nakandakare E . HDL-C concentration is related to markers of absorption and of cholesterol synthesis: Study in subjects with low vs. high HDL-C. Clin Chim Acta. 2010; 412(1-2):176-80. DOI: 10.1016/j.cca.2010.09.039. View

Fayad Z, Mani V, Woodward M, Kallend D, Abt M, Burgess T . Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet. 2011; 378(9802):1547-59. PMC: 4151875. DOI: 10.1016/S0140-6736(11)61383-4. View

10.

Kontush A . HDL-mediated mechanisms of protection in cardiovascular disease. Cardiovasc Res. 2014; 103(3):341-9. DOI: 10.1093/cvr/cvu147. View

11.

Ballantyne C, Miller M, Niesor E, Burgess T, Kallend D, Stein E . Effect of dalcetrapib plus pravastatin on lipoprotein metabolism and high-density lipoprotein composition and function in dyslipidemic patients: results of a phase IIb dose-ranging study. Am Heart J. 2012; 163(3):515-21, 521.e1-3. DOI: 10.1016/j.ahj.2011.11.017. View

12.

Fisher E, Feig J, Hewing B, Hazen S, Smith J . High-density lipoprotein function, dysfunction, and reverse cholesterol transport. Arterioscler Thromb Vasc Biol. 2012; 32(12):2813-20. PMC: 3501261. DOI: 10.1161/ATVBAHA.112.300133. View

13.

Ray K, Ditmarsch M, Kallend D, Niesor E, Suchankova G, Upmanyu R . The effect of cholesteryl ester transfer protein inhibition on lipids, lipoproteins, and markers of HDL function after an acute coronary syndrome: the dal-ACUTE randomized trial. Eur Heart J. 2014; 35(27):1792-800. DOI: 10.1093/eurheartj/ehu105. View

14.

Harchaoui K, Franssen R, Hovingh G, Bisoendial R, Stellaard F, Kuipers F . Reduced fecal sterol excretion in subjects with familial hypoalphalipoproteinemia. Atherosclerosis. 2009; 207(2):614-6. DOI: 10.1016/j.atherosclerosis.2009.06.022. View

15.

Niesor E, Chaput E, Staempfli A, Blum D, Derks M, Kallend D . Effect of dalcetrapib, a CETP modulator, on non-cholesterol sterol markers of cholesterol homeostasis in healthy subjects. Atherosclerosis. 2011; 219(2):761-7. DOI: 10.1016/j.atherosclerosis.2011.09.017. View

16.

Bisoendial R, Hovingh G, Harchaoui K, Levels J, Tsimikas S, Pu K . Consequences of cholesteryl ester transfer protein inhibition in patients with familial hypoalphalipoproteinemia. Arterioscler Thromb Vasc Biol. 2005; 25(9):e133-4. DOI: 10.1161/01.ATV.0000179009.60612.28. View

17.

Brunham L, Kruit J, Iqbal J, Fievet C, Timmins J, Pape T . Intestinal ABCA1 directly contributes to HDL biogenesis in vivo. J Clin Invest. 2006; 116(4):1052-62. PMC: 1401485. DOI: 10.1172/JCI27352. View

18.

. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002; 106(25):3143-421. View

19.

Schwartz G, Olsson A, Abt M, Ballantyne C, Barter P, Brumm J . Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012; 367(22):2089-99. DOI: 10.1056/NEJMoa1206797. View

20.

Robins S, Fasulo J . High density lipoproteins, but not other lipoproteins, provide a vehicle for sterol transport to bile. J Clin Invest. 1997; 99(3):380-4. PMC: 507809. DOI: 10.1172/JCI119170. View